Literature DB >> 8652374

CD30 ligand is expressed on resting normal and malignant human B lymphocytes.

A Younes1, U Consoli, S Zhao, V Snell, E Thomas, H J Gruss, F Cabanillas, M Andreeff.   

Abstract

CD30, a member of the tumour necrosis receptor superfamily, is physiologically expressed on a subpopulation of T helper cells in normal individuals but is also expressed on several malignant and virally transformed cells. Its ligand (CD30L) is a pleiotropic cellular transmembrane protein that can induce cell death in several CD30+ cell lines. CD30L expression has been reported on activated human peripheral blood T lymphocytes and macrophages but not on B cells. Here we show that the CD30L is expressed on resting normal and on malignant B cells in addition to both CD4+ and CD8+ subsets of activated T cells, making it the second tumour necrosis family member, in addition to the CD27 ligand, that can be expressed on both T and B cells. These findings raise the possibility that the CD30L has a role in B-cell/T-cell communication and that B and T cells are likely to be involved in the growth regulation of CD30+ tumours.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8652374     DOI: 10.1046/j.1365-2141.1996.d01-1686.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms.

Authors:  R Horie; V Gattei; K Ito; S Imajo-Ohmi; T Tange; J Miyauchi; A Pinto; M Degan; A De Iuliis; F Tassan Mazzocco; F M Rossi; M Higashihara; T Watanabe
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

3.  Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue.

Authors:  Joanne Fanelli Panus; Craig A Smith; Caroline A Ray; Terri Davis Smith; Dhavalkumar D Patel; David J Pickup
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 4.  Role of CD30 targeting in malignant lymphoma.

Authors:  Anita Kumar; Anas Younes
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 5.  Hodgkin's lymphoma and CD30 signal transduction.

Authors:  Ryouichi Horie; Masaaki Higashihara; Toshiki Watanabe
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

Review 6.  The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis.

Authors:  Ricardo F Antunes; Juan Carlos Kaski; Ingrid E Dumitriu
Journal:  J Biomed Biotechnol       Date:  2011-12-22

7.  Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis.

Authors:  Alessandro Barbieri; Marzia Dolcino; Elisa Tinazzi; Antonella Rigo; Giuseppe Argentino; Giuseppe Patuzzo; Andrea Ottria; Ruggero Beri; Antonio Puccetti; Claudio Lunardi
Journal:  J Immunol Res       Date:  2015-05-19       Impact factor: 4.818

8.  A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.

Authors:  Lorenzo Falchi; Daniela Capello; Barbara Palumbo; Annamaria Rauco; Rita Emili; Michele Cianciulli; Roberta Pace; Vincenzo Capparella; Fabrizio Liberati; Anna Marina Liberati
Journal:  Eur J Haematol       Date:  2007-10-01       Impact factor: 2.997

Review 9.  Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

Authors:  C A van der Weyden; S A Pileri; A L Feldman; J Whisstock; H M Prince
Journal:  Blood Cancer J       Date:  2017-09-08       Impact factor: 11.037

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.